Biopharma fundraising and dealmaking momentum stayed strong into late August, with Modernas latest capital raise and continuing high-value transaction flow underscoring risk-on activity. The week’s news flow included Moderna’s upsized note offering to support cancer work and additional sector updates reflecting sustained investor appetite for clinical-stage assets. Separately, coverage pointed to the broader market environment: July showed a near-record pace in biopharma M&A values, with deal totals rising year-over-year through the first seven months of 2026. The pattern reflects buyer preference for assets with less regulatory and clinical uncertainty, as well as continued consolidation across oncology and immunology. Overall, the funding and deal activity indicate that capital markets are still willing to underwrite late-stage and de-risked pipeline expansions as companies position ahead of patent cliffs and line-extension opportunities.